Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D ...
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief ...
Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...
CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of ...
Anyone who’s shed a tear (or a thousand) during Sarah McLachlan’s ASPCA commercial knows that as much as we might like to think of ourselves as purely logical beings, we’re often driven by our ...
Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results